Sermorelin

Vialdyne primary owner

Overview

Sermorelin is the unmodified 29-residue N-terminal fragment of native human GHRH (residues 1-29). The fragment retains the full receptor-binding activity of the parent 44-residue molecule, which is why Sermorelin became the historical reference compound against which every engineered GHRH analogue (CJC-1295, Tesamorelin, Modified GRF 1-29) has subsequently been benchmarked. Serum half-life is limited to roughly 10-12 minutes by DPP-4 cleavage at the Tyr1-Ala2 bond, and that exact PK constraint is what drove the subsequent design work behind the CJC-1295 family's substitution chemistry. Sermorelin itself was previously approved as a prescription drug (Geref) for paediatric GH-deficiency diagnostic use. Vialdyne releases Sermorelin acetate as a lyophilised powder against a ≥99.0% main-peak HPLC specification. The 29-residue length sits well within reliable SPPS range, and the standard release packet covers RP-HPLC peak integration, ESI-MS identity, Karl Fischer water, and counter-ion quantitation. In compounding-pharmacy practice, Sermorelin fits two niches: pulsatile-pattern GH-axis preparations where the short half-life is the right tool (the rapid clearance preserves natural GH pulse architecture), and short-acting clinical compounding where sustained elevation is undesirable. For sustained-action profiles, the CJC-1295 with DAC SKU is the appropriate alternative.

Applications & buyer fit

GH-axis peptides ship to two main buyer types: compounding pharmacies dispensing under physician supervision, and research labs studying somatotropic-axis pharmacology. Pharmacies typically want sterile-filled vials with the full release packet (sterility, endotoxin, CCI); labs typically want loose-format lyophilized powder with sequence verification. Blends (the CJC-1295 / Ipamorelin combination is the canonical example) are usually co-lyophilized rather than solution-mixed for potency stability.

Primary buyer fit: academic and contract research laboratories and 503A / 503B compounding pharmacies.

Specifications

CAS

86168-78-7

Sequence

YADAIFTNSYRKVLGQLSARKLLQDIMSR

Appearance

White to off-white lyophilized powder

Purity (HPLC)

≥ 99.0%

Strength

2 mg – 10 mg

Packaging

10 vials/box · base pack (multiples of 10)

Half-life

≈ 11-12 minutes

MOQ

On request

Lead time

7–14 days

Storage

-20°C, protect from light

Certificate of Analysis

Representative COA previews for Sermorelin; request the certificate matched to the offered or supplied lot from sales. These are previews — request the full high-resolution certificate for any lot.

VerifiedRequest full COA →

Sermorelin

VD260428-SERM10185 · 99.15%

VerifiedRequest full COA →

Sermorelin

VD260428-SERM183 · 99.36%

VerifiedRequest full COA →

Sermorelin

VD260428-SERM5184 · 98.93%

Regulatory note

Sold as a pharmaceutical-grade active for research and for compounding-pharmacy formulation where local regulations permit (notably 503A / 503B in the United States and analogous regimes elsewhere). Not a finished dosage form. Sterile-filled vials are available with full release documentation; the buyer is responsible for verifying scheduling and dispense requirements in the destination market.

Selected literature

1. Corpas E, Harman SM, Piñeyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-535.
2. Vittone J, Blackman MR, Busby-Whitehead J, Tsiao C, Stewart KJ, Tobin J, Stevens T, Bellantoni MF, Rogers MA, Baumann G, Roth J, Harman SM, Spencer RGS. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997;46(1):89-96.
3. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157.
4. Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308.
5. Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML; Endocrine Society. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(6):1587-1609.

Frequently asked questions